IL322968A - Semaglutide in medical treatment - Google Patents
Semaglutide in medical treatmentInfo
- Publication number
- IL322968A IL322968A IL322968A IL32296825A IL322968A IL 322968 A IL322968 A IL 322968A IL 322968 A IL322968 A IL 322968A IL 32296825 A IL32296825 A IL 32296825A IL 322968 A IL322968 A IL 322968A
- Authority
- IL
- Israel
- Prior art keywords
- semaglutide
- subject
- sema
- medicament
- administered
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17196254 | 2017-10-12 | ||
| PCT/EP2018/077654 WO2019072941A1 (en) | 2017-10-12 | 2018-10-10 | SEMAGLUTIDE IN MEDICAL THERAPY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL322968A true IL322968A (en) | 2025-10-01 |
Family
ID=60083831
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL322968A IL322968A (en) | 2017-10-12 | 2018-10-10 | Semaglutide in medical treatment |
| IL322969A IL322969A (en) | 2017-10-12 | 2018-10-10 | Semaglutide in medical therapy |
| IL273470A IL273470A (en) | 2017-10-12 | 2020-03-20 | Semaglutide in medical treatment |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL322969A IL322969A (en) | 2017-10-12 | 2018-10-10 | Semaglutide in medical therapy |
| IL273470A IL273470A (en) | 2017-10-12 | 2020-03-20 | Semaglutide in medical treatment |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US12029779B2 (https=) |
| EP (1) | EP3694538A1 (https=) |
| JP (2) | JP7148605B2 (https=) |
| KR (1) | KR20200069316A (https=) |
| CN (4) | CN120241968A (https=) |
| AU (2) | AU2018348929B2 (https=) |
| BR (1) | BR112020006246A2 (https=) |
| CA (1) | CA3078652A1 (https=) |
| CL (1) | CL2020000812A1 (https=) |
| IL (3) | IL322968A (https=) |
| MA (1) | MA50358A (https=) |
| MX (3) | MX2020003049A (https=) |
| MY (1) | MY204827A (https=) |
| PH (1) | PH12020550185A1 (https=) |
| SG (1) | SG11202002841PA (https=) |
| TW (1) | TWI842681B (https=) |
| WO (1) | WO2019072941A1 (https=) |
| ZA (3) | ZA202503387B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7148605B2 (ja) * | 2017-10-12 | 2022-10-05 | ノヴォ ノルディスク アー／エス | 医学療法におけるセマグルチド |
| EP4104820A4 (en) | 2020-02-14 | 2024-04-17 | G2GBIO, Inc. | Pharmaceutical composition comprising sustained-release microspheres including glp-1 analogue or pharmaceutically acceptable salt thereof |
| PE20230819A1 (es) | 2020-02-18 | 2023-05-19 | Novo Nordisk As | Composiciones y usos de glp-1 |
| US11478533B2 (en) * | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
| EP4313016A4 (en) * | 2021-03-29 | 2025-01-22 | Sanford Health | METHODS AND COMPOSITIONS FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES |
| AU2023285400A1 (en) * | 2022-06-08 | 2024-12-05 | Zydus Lifesciences Limited | Reusable multi-dose, variable dose, single pen injector for type 2 diabetes and weight management |
| WO2024249659A2 (en) * | 2023-05-30 | 2024-12-05 | The Medical College Of Wisconsin, Inc. | Methods for weight loss and/or reducing weight gain |
| US12597496B2 (en) * | 2023-06-05 | 2026-04-07 | Closed Loop Medicine Ltd. | Dosing of incretin pathway drugs |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6268343B1 (en) | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| AU2002316811A1 (en) | 2001-06-28 | 2003-03-03 | Novo Nordisk A/S | Stable formulation of modified glp-1 |
| KR101241862B1 (ko) | 2003-09-19 | 2013-03-13 | 노보 노르디스크 에이/에스 | 신규 ｇｌｐ-1 유도체 |
| TR201906789T4 (tr) | 2003-11-20 | 2019-05-21 | Novo Nordisk As | Üretim ve enjeksiyon cihazlarında kullanım için en uygun olan propilen glikol ihtiva eden peptit formülasyonları. |
| RU2413530C9 (ru) | 2004-11-12 | 2021-05-18 | Ново Нордиск А/С | Стабильные препараты инсулинотропных пептидов |
| TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| MX373000B (es) | 2005-09-14 | 2020-05-21 | Mannkind Corp | Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas. |
| MX2008013216A (es) | 2006-04-14 | 2008-10-27 | Mannkind Corp | Formulaciones farmaceuticas de peptido-1 tipo glucagon (glp-1). |
| EP2481410B1 (en) | 2007-01-31 | 2016-07-13 | BIAL - Portela & Ca., S.A. | Nitrocatechol derivates as COMT inhibitors administered with a specific dosage regime |
| WO2008116088A1 (en) | 2007-03-20 | 2008-09-25 | Nippon Kayaku Kabushiki Kaisha | Method to monitor drug efficacy in diabetic patients using an assay for 1,5-anhydro-d-glucitol |
| WO2009030774A1 (en) | 2007-09-05 | 2009-03-12 | Novo Nordisk A/S | Truncated glp-1 derivatives and their therapeutical use |
| US8748377B2 (en) | 2008-12-10 | 2014-06-10 | Glaxosmithkline Llc | Pharmaceutical compositions |
| EP2395988A2 (en) | 2009-02-13 | 2011-12-21 | Boehringer Ingelheim International GmbH | Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics |
| EP2512518A1 (en) | 2009-12-16 | 2012-10-24 | Novo Nordisk A/S | Glp-1 receptor agonist compounds with a modified n-terminus |
| CA3070513C (en) | 2010-05-05 | 2023-01-03 | Boehringer Ingelheim International Gmbh | A dpp-4 inhibitor for use in treatment of skin-alterations or necrosis |
| WO2012016419A1 (zh) | 2010-08-06 | 2012-02-09 | 浙江贝达药业有限公司 | Glp-1衍生物及其应用 |
| MX377589B (es) | 2010-12-16 | 2025-03-10 | Novo Nordisk As | Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico. |
| SG191252A1 (en) | 2010-12-22 | 2013-07-31 | Marcadia Biotech Inc | Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides |
| US20130035281A1 (en) | 2011-02-09 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CN102718858B (zh) | 2011-03-29 | 2014-07-02 | 天津药物研究院 | 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用 |
| WO2012136790A1 (en) | 2011-04-07 | 2012-10-11 | Glaxo Group Limited | Compositions comprising fusion proteins or conjugates with an improved half -life |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| CN102229668A (zh) | 2011-06-03 | 2011-11-02 | 浙江贝达药业有限公司 | 一种glp-1衍生物及其应用 |
| US20140220134A1 (en) | 2011-06-24 | 2014-08-07 | Astrazeneca Pharamceuticals LP | Method for treating diabetes with extended release formulation of glp-1 receptor agonists |
| LT2753312T (lt) | 2011-09-08 | 2017-01-25 | Mereo Biopharma 2 Limited | Aromatazės inhibitoriaus panaudojimas hipogonadizmo ir susijusių ligų gydymui |
| JP6250034B2 (ja) * | 2012-05-08 | 2017-12-20 | ノヴォ ノルディスク アー／エス | 二重アシル化されたｇｌｐ−１誘導体 |
| NZ727849A (en) | 2012-06-29 | 2018-06-29 | Amarin Pharmaceuticals Ie Ltd | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
| HRP20251088T1 (hr) | 2012-07-01 | 2025-11-07 | Novo Nordisk A/S | Upotreba dugodjelujućih peptida glp‑1 |
| JP6672140B2 (ja) * | 2013-05-02 | 2020-03-25 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１化合物の経口投薬 |
| KR102844773B1 (ko) | 2015-12-23 | 2025-08-13 | 암젠 인크 | 위 억제 펩티드 수용체 (gipr)에 대한 결합 단백질을 glp-1 효능제와 조합하여 사용하여 대사 장애를 치료하거나 개선시키는 방법 |
| JP2020529440A (ja) | 2017-08-04 | 2020-10-08 | オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 糖尿病および関連する状態の処置におけるガボキサドールの使用 |
| JP7148605B2 (ja) | 2017-10-12 | 2022-10-05 | ノヴォ ノルディスク アー／エス | 医学療法におけるセマグルチド |
-
2018
- 2018-10-10 JP JP2020517328A patent/JP7148605B2/ja active Active
- 2018-10-10 MY MYPI2020001658A patent/MY204827A/en unknown
- 2018-10-10 AU AU2018348929A patent/AU2018348929B2/en active Active
- 2018-10-10 KR KR1020207012311A patent/KR20200069316A/ko active Pending
- 2018-10-10 CN CN202510086779.1A patent/CN120241968A/zh active Pending
- 2018-10-10 CN CN202411858188.3A patent/CN119950682A/zh active Pending
- 2018-10-10 BR BR112020006246-4A patent/BR112020006246A2/pt not_active Application Discontinuation
- 2018-10-10 CN CN201880066425.9A patent/CN111212657A/zh not_active Withdrawn
- 2018-10-10 CN CN202510084667.2A patent/CN119838000A/zh active Pending
- 2018-10-10 CA CA3078652A patent/CA3078652A1/en active Pending
- 2018-10-10 IL IL322968A patent/IL322968A/en unknown
- 2018-10-10 SG SG11202002841PA patent/SG11202002841PA/en unknown
- 2018-10-10 MA MA050358A patent/MA50358A/fr unknown
- 2018-10-10 WO PCT/EP2018/077654 patent/WO2019072941A1/en not_active Ceased
- 2018-10-10 MX MX2020003049A patent/MX2020003049A/es unknown
- 2018-10-10 EP EP18788709.6A patent/EP3694538A1/en active Pending
- 2018-10-10 IL IL322969A patent/IL322969A/en unknown
- 2018-10-12 TW TW107136028A patent/TWI842681B/zh active
-
2020
- 2020-03-19 MX MX2025002189A patent/MX2025002189A/es unknown
- 2020-03-19 MX MX2025002188A patent/MX2025002188A/es unknown
- 2020-03-20 IL IL273470A patent/IL273470A/en unknown
- 2020-03-27 CL CL2020000812A patent/CL2020000812A1/es unknown
- 2020-03-27 PH PH12020550185A patent/PH12020550185A1/en unknown
- 2020-04-09 US US16/844,552 patent/US12029779B2/en active Active
-
2022
- 2022-07-13 JP JP2022112446A patent/JP7475398B2/ja active Active
-
2024
- 2024-06-07 US US18/736,608 patent/US20240316159A1/en not_active Abandoned
- 2024-08-30 US US18/820,792 patent/US12295988B2/en active Active
-
2025
- 2025-04-09 US US19/174,121 patent/US12551536B2/en active Active
- 2025-04-22 ZA ZA2025/03387A patent/ZA202503387B/en unknown
- 2025-04-22 ZA ZA2025/03388A patent/ZA202503388B/en unknown
- 2025-04-22 ZA ZA2025/03350A patent/ZA202503350B/en unknown
- 2025-05-15 AU AU2025203535A patent/AU2025203535A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12295988B2 (en) | Semaglutide in medical therapy | |
| EA034940B1 (ru) | Лечение пациентов с сахарным диабетом 2 типа | |
| US20240100127A1 (en) | Tirzepatide therapeutic methods | |
| US11607441B2 (en) | Pharmaceutical composition for preventing or treating diabetes, containing zinc salt, cyclo-hispro and antidiabetic drug as active ingredients | |
| RU2800651C2 (ru) | Семаглутид в лекарственной терапии | |
| WO2021224338A1 (en) | Treatment of hyperuricemia | |
| US20210100872A1 (en) | Pharmacological Formulation Comprising Cyclo (HIS-PRO) As Effective Ingredient For Preventing Or Treating Diabetes Mellitus | |
| BR122025013280A2 (pt) | Uso de semaglutida para fabricar uma solução injetável subcutânea para tratar diabetes tipo 2 | |
| US20250360183A1 (en) | Use of gmi from ganoderma lucidum spores in the preparation of pharmaceuticals and food products | |
| US20260053769A1 (en) | Uses of selective androgen receptor modulator (sarm) compounds for quality weight loss | |
| US20250228804A1 (en) | Uses of selective androgen receptor modulator (sarm) compounds for quality weight loss | |
| BR122024015864A2 (pt) | Uso de semaglutida para preparação de uma composição farmacêutica para controle de peso | |
| BR122024015868A2 (pt) | Uso de semaglutida para preparação de uma composição farmacêutica para tratamento e/ou prevenção de obesidade e/ou de sobrepeso | |
| CN121969358A (zh) | 选择性雄激素受体调节剂（sarm）化合物在长期体重管理中的用途 | |
| AU2024355562A1 (en) | Uses of selective androgen receptor modulator (sarm) compounds in chronic weight management |